Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Feb;29(2):298–302. doi: 10.1128/aac.29.2.298

Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora.

T Bergan, C Delin, S Johansen, I M Kolstad, C E Nord, S B Thorsteinsson
PMCID: PMC176395  PMID: 2940965

Abstract

The pharmacokinetics of ciprofloxacin was studied in 12 volunteers during a 5-day course of 500 mg of ciprofloxacin given orally twice a day. The effects on the microflora of saliva and feces were also examined. Serum and urine samples were assayed for ciprofloxacin microbiologically, and the salivary and fecal microflora were examined quantitatively after processing onto a series of selective media. Fecal samples were also investigated for the presence of Clostridium difficile and its cytotoxin. The MICs for new colonizing bacteria were examined in the salivary and fecal samples. There was no accumulation during the course of 5 days with peak serum concentrations identical (2.8 and 2.3 mg/liter) after the first and final doses, and the areas under the serum curves were similar (9.6 mg/liter). The serum half-life was 2.5 h on both days. The changes in the salivary flora were minor and affected only the neisseriae. In the fecal flora, the numbers of enterobacteria and enterococci decreased markedly, whereas the changes in anaerobic flora (anaerobic cocci, fusobacteria, and bacteroids) were not so pronounced. However, 14 days after the drug was discontinued, the salivary and fecal flora were normalized in all respects. No new colonization of ciprofloxacin-resistant bacteria for which MICs were above 1.0 mg/liter was observed. C. difficile or its cytotoxin was not detected.

Full text

PDF
298

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aronsson B., Möllby R., Nord C. E. Diagnosis and epidemiology of Clostridium difficile enterocolitis in Sweden. J Antimicrob Chemother. 1984 Dec;14 (Suppl 500):85–95. doi: 10.1093/jac/14.suppl_d.85. [DOI] [PubMed] [Google Scholar]
  2. Brumfitt W., Franklin I., Grady D., Hamilton-Miller J. M., Iliffe A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother. 1984 Nov;26(5):757–761. doi: 10.1128/aac.26.5.757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chin N. X., Neu H. C. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1984 Mar;25(3):319–326. doi: 10.1128/aac.25.3.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dalhoff A., Weidner W. Diffusion of ciprofloxacin into prostatic fluid. Eur J Clin Microbiol. 1984 Aug;3(4):360–362. doi: 10.1007/BF01977495. [DOI] [PubMed] [Google Scholar]
  5. Heimdahl A., Nord C. E. Effect of phenoxymethylpenicillin and clindamycin on the oral, throat and faecal microflora of man. Scand J Infect Dis. 1979;11(3):233–242. doi: 10.3109/inf.1979.11.issue-3.11. [DOI] [PubMed] [Google Scholar]
  6. Hoogkamp-Korstanje J. A. Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy. Eur J Clin Microbiol. 1984 Aug;3(4):333–338. doi: 10.1007/BF01977489. [DOI] [PubMed] [Google Scholar]
  7. Kemmerich B., Warns H., Lode H., Borner K., Koeppe P., Knothe H. Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother. 1983 Sep;24(3):333–338. doi: 10.1128/aac.24.3.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Knothe H., Wiedemann B. Die Wirkung von Ampicillin auf die Darmflora des gesunden Menschen. Zentralbl Bakteriol Orig. 1965 Aug;197(2):234–243. [PubMed] [Google Scholar]
  9. Nord C. E., Kager L., Heimdahl A. Impact of antimicrobial agents on the gastrointestinal microflora and the risk of infections. Am J Med. 1984 May 15;76(5A):99–106. doi: 10.1016/0002-9343(84)90250-x. [DOI] [PubMed] [Google Scholar]
  10. Shrire L., Saunders J., Traynor R., Koornhof H. J. A laboratory assessment of ciprofloxacin and comparable antimicrobial agents. Eur J Clin Microbiol. 1984 Aug;3(4):328–332. doi: 10.1007/BF01977488. [DOI] [PubMed] [Google Scholar]
  11. Wingender W., Graefe K. H., Gau W., Förster D., Beermann D., Schacht P. Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin Microbiol. 1984 Aug;3(4):355–359. doi: 10.1007/BF01977494. [DOI] [PubMed] [Google Scholar]
  12. Wise R., Lockley R. M., Webberly M., Dent J. Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother. 1984 Aug;26(2):208–210. doi: 10.1128/aac.26.2.208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Zeiler H. J., Grohe K. The in vitro and in vivo activity of ciprofloxacin. Eur J Clin Microbiol. 1984 Aug;3(4):339–343. doi: 10.1007/BF01977490. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES